Yale Ventures Accelerates Innovation with Groundbreaking Drug Delivery Tech

Developmental biologist Anne Eichmann's lab discovers D2B3 technology that could revolutionize neurology by temporarily opening the blood-brain barrier.

Mar. 5, 2026 at 4:30am

Got story updates? Submit your updates here. ›

Anne Eichmann, a developmental biologist and professor at Yale School of Medicine, has made a breakthrough discovery in her lab - a drug delivery technology called D2B3 that can temporarily and reversibly open the blood-brain barrier. This natural defense mechanism normally prevents potentially life-saving drugs from reaching the brain, but Eichmann's D2B3 technology could change that and make a big difference for people suffering from neurological conditions. Eichmann was able to translate her research into real-world impact thanks to support from The Blavatnik Fund for Innovation at Yale, which has helped transform the university's leading research into life-saving solutions.

Why it matters

The blood-brain barrier is a major obstacle in delivering drugs to treat neurological diseases and conditions. Eichmann's D2B3 technology could potentially open up new treatment possibilities for a wide range of brain-related illnesses and disorders by enabling more effective drug delivery. This breakthrough highlights Yale's role as a hub of scientific innovation and the importance of programs like the Blavatnik Fund that help bridge the gap between academic research and real-world applications.

The details

Eichmann's lab at Yale has developed a groundbreaking drug delivery technology called D2B3 that can temporarily and reversibly open the blood-brain barrier. This natural defense mechanism normally prevents many potentially therapeutic drugs from reaching the brain. By overcoming this barrier, the D2B3 technology has the potential to revolutionize the treatment of neurological conditions. Eichmann was able to advance her research from the lab to real-world impact with support from The Blavatnik Fund for Innovation at Yale, which has helped transform the university's leading scientific discoveries into life-saving solutions since 2017.

  • Eichmann's lab at Yale has been working on the D2B3 technology for several years.
  • The Blavatnik Fund for Innovation at Yale has been supporting the translation of university research into real-world applications since 2017.

The players

Anne Eichmann

The Ensign Professor of Medicine (Cardiovascular Medicine) at Yale School of Medicine and professor of cellular and molecular physiology in Yale's Faculty of Arts and Sciences. Eichmann's lab at Yale has developed the groundbreaking D2B3 drug delivery technology.

The Blavatnik Fund for Innovation at Yale

A fund that has helped transform Yale University's field-leading research into life-saving solutions across the life sciences since 2017.

Got photos? Submit your photos here. ›

What they’re saying

“You get to a point where you see that what you discovered could actually be good for humanity going forward.”

— Anne Eichmann, Ensign Professor of Medicine (Cardiovascular Medicine), Yale School of Medicine

What’s next

The Blavatnik Fund for Innovation at Yale will continue supporting Eichmann and her team as they work to further develop and translate the D2B3 technology into real-world applications that could benefit patients suffering from neurological conditions.

The takeaway

Yale's robust research ecosystem, combined with programs like the Blavatnik Fund, are enabling groundbreaking discoveries like Eichmann's D2B3 technology to move from the lab to making a tangible impact on people's lives. This highlights the university's role as a hub of scientific innovation and the importance of bridging the gap between academic research and real-world solutions.